医学交流课件：AZ China COPD ATS ERS 2 Russell.pptxVIP

;2;;Lymington New Forest Hospital;Presenter disclosures: I have no shares in Pharmaceutical companies and do everything I can to hinder tobacco companies;What am I going to cover?;Progress is being made in COPD: The world is changing for the better…;At presentation, patients typically show:1–6 Significant airflow limitation Symptoms of breathlessness Impaired QoL at presentation;1. Mapel DW, et al. Int J Chron Obstruct Pulmon Dis 2011;6:573?581; 2. Price D, et al. Prim Care Respir J 2011;20:15–22. ;FEV1 decline: the traditional view;;Predictors of lung function decline in smokers in COPDGene Phase 2 ;COPD Exacerbations;Problems with the GOLD classification;15;What may be driving this?;Classification by GOLD is NOT stable;Who is the “High Risk” Patient? Not as simple as GOLD…;19;20;And exacerbations are associated with mortality…;How do you treat them?;The return of GOLD 0?;A new concept?;How can eosinophils help to guide treatment in acute exacerbations?;Should treatment be a question of eosinophil levels?;Analysis of four large trial populations for predictive role of blood eosinophils;Eosinophils and ICS;29;Eosinophils in COPD: a story with 2 parts;ACOS: is CHAOS!;ACOS – the question of overlap syndrome or coincidental morbidity remains controversial;ACOS evaluation by new GOLD classification – an analysis from the COPDGene Investigators;Review Article The Asthma–COPD Overlap Syndrome;Exacerbations: not just a lung thing!;The pathology of cognitive dysfunction in COPD:White matter is under attack;A troika of negative impact: anxiety, depression and cognitive dysfunction;E-cigarettes ? What’s new? A quick look ;;Do e-cigarettes help smokers quit?;Pulmonary rehabilitation;Problems with recruitment to programmes and completion rates;Current COPD;